Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
X4 Pharmaceuticals, Inc. (XFOR)
USD3.81
-0.21 (-5.16%)
US NASDAQ Healthcare Biotechnology
Address
61 North Beacon Street 2134
Boston, MA, US
Boston, MA, US
CEO
Adam R. Craig
Website
x4pharma.com
IPO
2017-11-16
CIK 1501697 ISIN US98420X2027
Description
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Actelis Networks, Inc. | ASNS | 2018-12-20 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.81
-0.21 (-5.16%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
589.2K
Beta
0.37
Float Shares
6.50M
Free Float %
57.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.58% | +6.64% | +9.76% | +33.53% | +16.28% | +12.50% | +34.73% | -89.80% | -98.13% | -99.82% | -99.82% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
3.81
Low
10.00
+162.3%
Consensus
11.00
+188.5%
Median
11.00
+188.5%
High
12.00
+214.7%
DCF (Unlevered)
23.22
+509.1%
DCF (Levered)
2.61
-31.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
12.00
+214.7%
|
| Last Year | 5 |
8.40
+120.3%
|
| All Time | 8 |
6.63
+73.9%
|
Quality scores
Altman Z-Score
-3.22
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+1,273.2% ★ Q1'26: -90.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+66.6% ★ Q1'26: -500.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-280.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-247.4% Q1'26: -749.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-821.4% Q1'26: +125.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+531.0% Q1'26: +1,738.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.90× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.00M
est: 3.00M (+0.0%)
|
—
est: 563.0K (-100.0%)
|
2.56M
est: 2.20M (+16.3%)
|
35.11M
est: 34.24M (+2.5%)
|
9.07M
7.55M – 10.59M
-73.5% YoY
|
9.17M
7.22M – 11.11M
+1.1% YoY
|
130.30M
106.17M – 160.03M
+1,321.5% YoY
|
333.40M
271.65M – 409.47M
+155.9% YoY
|
715.50M
582.97M – 878.75M
+114.6% YoY
|
| EBITDA |
-58.64M
est: 600.0K (-9,874.0%)
|
-94.89M
est: 112.6K (-84,375.2%)
|
-27.58M
est: 439.7K (-6,371.1%)
|
-85.61M
est: 6.85M (-1,349.9%)
|
1.81M
1.51M – 2.12M
-73.5% YoY
|
1.83M
1.44M – 2.22M
+1.1% YoY
|
26.06M
21.23M – 32.01M
+1,321.5% YoY
|
66.68M
54.33M – 81.89M
+155.9% YoY
|
143.10M
116.59M – 175.75M
+114.6% YoY
|
| EBIT |
-59.87M
est: 600.0K (-10,079.0%)
|
-95.31M
est: 112.6K (-84,747.3%)
|
-28.37M
est: 439.7K (-6,552.1%)
|
-86.88M
est: 6.85M (-1,368.6%)
|
1.81M
1.51M – 2.12M
-73.5% YoY
|
1.83M
1.44M – 2.22M
+1.1% YoY
|
26.06M
21.23M – 32.01M
+1,321.5% YoY
|
66.68M
54.33M – 81.89M
+155.9% YoY
|
143.10M
116.59M – 175.75M
+114.6% YoY
|
| Net Income |
-62.13M
est: -625.33M (+90.1%)
|
-101.17M
est: 3.85M (-2,729.3%)
|
-37.45M
est: -159.79M (+76.6%)
|
-79.20M
est: -99.72M (+20.6%)
|
-31.37M
-35.27M – -27.48M
+68.5% YoY
|
-32.99M
-41.79M – -24.19M
-5.1% YoY
|
-25.59M
-40.03M – -11.14M
+22.4% YoY
|
8.67M
6.58M – 11.24M
+133.9% YoY
|
77.18M
58.60M – 100.08M
+790.2% YoY
|
| SGA |
20.94M
est: 20.42M (+2.5%)
|
35.51M
est: 3.19M (+1,014.3%)
|
61.52M
est: 12.44M (+394.4%)
|
43.52M
est: 193.81M (-77.5%)
|
51.31M
42.71M – 59.92M
-73.5% YoY
|
51.88M
40.87M – 62.88M
+1.1% YoY
|
737.45M
600.85M – 905.70M
+1,321.5% YoY
|
1.89B
1.54B – 2.32B
+155.9% YoY
|
4.05B
3.30B – 4.97B
+114.6% YoY
|
| EPS |
-92.84
est: -93.31 (+0.5%)
|
-17.07
est: 0.09 (-19,386.4%)
|
-5.59
est: -3.90 (-43.3%)
|
-1.87
est: -2.04 (+8.2%)
|
-0.75
-0.83 – -0.65
+63.4% YoY
|
-0.78
-0.99 – -0.57
-4.5% YoY
|
-0.61
-0.95 – -0.26
+22.4% YoY
|
0.21
0.16 – 0.27
+133.9% YoY
|
1.83
1.39 – 2.37
+790.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-116.54M
OE per share TTM
-4.95
Owner's Yield
-21.07%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
106.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
5
Total invested
48.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
46
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Anders Hove | 17.76M | 9.99% | — | 17.76M | — | — | IN | United States of America | 2024-02-14 | ↗ |
| 2 | Acorn Bioventures 2 L.P. | 11.39M | 6.50% | — | 11.39M | — | — | PN | Delaware | 2024-02-14 | ↗ |
| 3 | Acorn Capital Advisors GP 2, LLC | 11.39M | 6.50% | — | 11.39M | — | — | OO | Delaware | 2024-02-14 | ↗ |
| 4 | (1) BlackRock, Inc. | 11.21M | 6.70% | 11.14M | — | 11.21M | — | HC | Delaware | 2024-11-08 | ↗ |
| 5 | Israel A. Englander | 8.27M | 5.20% | — | 8.27M | — | 8.27M | IN | — | 2023-06-16 | ↗ |
| 6 | Millennium Group Management LLC | 8.27M | 5.20% | — | 8.27M | — | 8.27M | OO | — | 2023-06-16 | ↗ |
| 7 | Millennium Management LLC | 8.27M | 5.20% | — | 8.27M | — | 8.27M | OO | — | 2023-06-16 | ↗ |
| 8 | Acorn Bioventures, L.P. | 8.21M | 4.80% | — | 8.21M | — | — | PN | Delaware | 2024-02-14 | ↗ |
| 9 | Acorn Capital Advisors GP, LLC | 8.21M | 4.80% | — | 8.21M | — | — | OO | Delaware | 2024-02-14 | ↗ |
| 10 | Ali Behbahani | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 11 | Anthony A. Florence, Jr. | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 12 | Carmen Chang | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 13 | Edward T. Mathers | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 14 | Growth Equity Opportunities 18 VGE, LLC | 6.88M | 9.90% | — | 6.88M | — | 6.88M | OO | Delaware Limited Liability Company | 2022-07-19 | ↗ |
| 15 | Liza Landsman | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 16 | Mohamad H. Makhzoumi | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 17 | NEA 18 VGE GP, LLC | 6.88M | 9.90% | — | 6.88M | — | 6.88M | OO | Limited Liability Company | 2022-07-19 | ↗ |
| 18 | NEA 18 Venture Growth Equity, L.P. | 6.88M | 9.90% | — | 6.88M | — | 6.88M | PN | Delaware Limited Partnership | 2022-07-19 | ↗ |
| 19 | NEA Partners 18 VGE, L.P. | 6.88M | 9.90% | — | 6.88M | — | 6.88M | PN | Delaware Limited Partnership | 2022-07-19 | ↗ |
| 20 | Paul Walker | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 21 | Peter W. Sonsini | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 22 | Rick Yang | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 23 | Scott D. Sandell | 6.88M | 9.90% | — | 6.88M | — | 6.88M | IN | States | 2022-07-19 | ↗ |
| 24 | Empery Asset Management, LP | 4.55M | 5.12% | — | 4.55M | — | — | PN | Delaware | 2023-01-13 | ↗ |
| 25 | Martin D. Hoe | 4.55M | 5.12% | — | 4.55M | — | — | IN | United States | 2023-01-13 | ↗ |
| 26 | Ryan M. Lane | 4.55M | 5.12% | — | 4.55M | — | — | IN | United States | 2023-01-13 | ↗ |
| 27 | OrbiMed Advisors LLC | 1.84M | 6.40% | — | 1.84M | — | — | IA | Delaware | 2022-02-11 | ↗ |
| 28 | OrbiMed Capital GP IV LLC | 1.84M | 6.40% | — | 1.84M | — | — | OO | Delaware | 2022-02-11 | ↗ |
| 29 | Alex Noah Investors, Inc. | 1.81M | 6.44% | — | 1.81M | — | — | CO | Illinois | 2022-01-19 | ↗ |
| 30 | Jonathan I. Cope | 1.81M | 6.44% | — | 1.81M | — | — | IN | Illinois | 2022-01-19 | ↗ |
| 31 | Joshua B. Scheinfeld | 1.81M | 6.44% | — | 1.81M | — | — | IN | Illinois | 2022-01-19 | ↗ |
| 32 | Lincoln Park Capital Fund, LLC | 1.81M | 6.44% | — | 1.81M | — | — | OO | Illinois | 2022-01-19 | ↗ |
| 33 | Lincoln Park Capital, LLC | 1.81M | 6.44% | — | 1.81M | — | — | OO | Illinois | 2022-01-19 | ↗ |
| 34 | Rockledge Capital Corporation | 1.81M | 6.44% | — | 1.81M | — | — | CO | Illinois | 2022-01-19 | ↗ |
| 35 | Point72 Asset Management, L.P. | 1.63M | 4.00% | — | 1.63M | — | 1.63M | PN | Delaware | 2022-02-14 | ↗ |
| 36 | Steven A. Cohen | 1.50M | 4.00% | — | 1.50M | — | 1.50M | IN | United States | 2021-11-17 | ↗ |
| 37 | Point72 Capital Advisors, Inc. | 1.50M | 4.00% | — | 1.50M | — | 1.50M | CO | United States | 2021-11-17 | ↗ |
| 38 | (. | 1.46M | 6.20% | 1.46M | — | 1.46M | — | IN | United States | 2021-06-29 | ↗ |
| 39 | 27-4413262 | 1.46M | 6.20% | 1.46M | — | 1.46M | — | OO | Maryland | 2021-06-29 | ↗ |
| 40 | Peter Kolchinsky | 1.14M | 3.90% | — | 1.14M | — | — | HC, IN | Delaware | 2022-02-14 | ↗ |
| 41 | RA Capital Healthcare Fund, L.P. | 1.14M | 3.90% | — | 1.14M | — | — | HC, IN | Delaware | 2022-02-14 | ↗ |
| 42 | RA Capital Management, L.P. | 1.14M | 3.90% | — | 1.14M | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 43 | Rajeev Shah | 1.14M | 3.90% | — | 1.14M | — | — | HC, IN | Delaware | 2022-02-14 | ↗ |
| 44 | Neil Shahrestani | 826.4K | 5.10% | — | 826.4K | — | 826.4K | HC, IN | Delaware | 2020-12-30 | ↗ |
| 45 | Ikarian Healthcare Master Fund, L.P. | 663.8K | 4.10% | — | 663.8K | — | 663.8K | PN | Delaware | 2020-12-30 | ↗ |
| 46 | Cubist Systematic Strategies, LLC | 243.00 | 4.00% | — | 243.00 | — | 243.00 | OO | United States | 2021-11-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
5
-71 vs prev Q
New positions
0
Closed positions
70
Increased
1
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EMPERY ASSET MANAGEMENT, LP | 8.95M +9.0M (+100.0%) | 35.80B +35.8B (+100.0%) | 120.75% +120.749 pp | 31.57% +31.573 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 2 | — | 3.72M +3.7M (+100.0%) | 14.89B +14.9B (+100.0%) | 50.22% +50.221 pp | 14.73% +14.729 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 3 | FMR LLC | 8.50M +8.5M (+100.0%) | 34.00M +34.0M (+100.0%) | 114.65% +114.651 pp | 0.00% +0.002 pp | USD4.00 +0.0% | 3 qtrs — |
| 4 | MORGAN STANLEY | 8.21M +8.2M (+220,072.1%) | 32.83M +32.8M (+257,406.4%) | 110.72% +110.675 pp | 0.00% +0.002 pp | USD4.00 +0.0% | 3 qtrs — |
| 5 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 7.97M +5.5M (+227.0%) | 31.87M +23.5M (+282.4%) | 107.48% +74.611 pp | 2.44% +1.888 pp | USD3.72 +7.5% | 3 qtrs — |
| 6 | PERCEPTIVE ADVISORS LLC | 6.31M +6.3M (+100.0%) | 25.26M +25.3M (+100.0%) | 85.18% +85.181 pp | 0.45% +0.450 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 7 | SATURN V CAPITAL MANAGEMENT LLC | 5.80M +5.8M (+100.0%) | 23.20M +23.2M (+100.0%) | 78.25% +78.248 pp | 4.26% +4.258 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 8 | DEEP TRACK CAPITAL, LP | 5.01M +3.9M (+346.7%) | 20.05M +16.2M (+422.4%) | 67.63% +52.491 pp | 0.36% +0.250 pp | USD3.87 +3.4% | 2 qtrs — |
| 9 | VANGUARD GROUP INC | 3.42M +3.0M (+734.1%) | 13.69M +12.3M (+875.5%) | 46.18% +40.647 pp | 0.00% +0.000 pp | USD3.83 +4.4% | 3 qtrs — |
| 10 | BRAIDWELL LP | 3.37M +3.4M (+100.0%) | 13.48M +13.5M (+100.0%) | 45.45% +45.446 pp | 0.43% +0.431 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 11 | BLACKSTONE INC. | 2.68M +2.7M (+100.0%) | 10.73M +10.7M (+100.0%) | 36.18% +36.179 pp | 0.04% +0.042 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 12 | ROSALIND ADVISORS, INC. | 2.61M +1.1M (+68.7%) | 10.42M +5.1M (+97.3%) | 35.15% +14.317 pp | 3.66% +1.858 pp | USD3.66 +9.3% | 2 qtrs — |
| 13 | NANTAHALA CAPITAL MANAGEMENT, LLC | 2.45M +221.1K (+9.9%) | 9.80M +2.2M (+28.6%) | 33.04% +2.983 pp | 0.32% +0.059 pp | USD3.47 +15.3% | 2 qtrs — |
| 14 | BVF INC/IL | 2.23M +— (+0.0%) | 8.93M +1.3M (+17.0%) | 30.13% +0.000 pp | 0.30% -0.009 pp | USD3.42 +17.0% | 2 qtrs — |
| 15 | SAMSARA BIOCAPITAL, LLC | 1.96M +2.0M (+100.0%) | 7.84M +7.8M (+100.0%) | 26.44% +26.440 pp | 0.81% +0.809 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 16 | SIREN, L.L.C. | 1.50M +1.5M (+100.0%) | 6.00M +6.0M (+100.0%) | 20.23% +20.235 pp | 0.18% +0.179 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 17 | BLACKROCK, INC. | 1.23M +1.2M (+1,880.8%) | 4.91M +4.7M (+2,216.8%) | 16.55% +15.714 pp | 0.00% +0.000 pp | USD3.89 +2.8% | 3 qtrs — |
| 18 | WOODLINE PARTNERS LP | 1.00M +1.0M (+100.0%) | 4.00M +4.0M (+100.0%) | 13.50% +13.501 pp | 0.02% +0.016 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 940.4K +860.8K (+1,080.6%) | 3.76M +3.5M (+1,281.4%) | 12.69% +11.612 pp | 0.00% +0.000 pp | USD3.87 +3.4% | 3 qtrs — |
| 20 | STEMPOINT CAPITAL LP | 898.5K +343.1K (+61.8%) | 3.59M +1.7M (+89.2%) | 12.12% +4.628 pp | 0.62% +0.236 pp | USD3.64 +9.9% | 2 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 831.9K +831.9K (+100.0%) | 3.33M +3.3M (+100.0%) | 11.22% +11.222 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 3 qtrs — |
| 22 | POINT72 ASSET MANAGEMENT, L.P. | 808.2K +786.5K (+3,630.1%) | 3.23M +3.2M (+4,262.6%) | 10.90% +10.610 pp | 0.00% +0.004 pp | USD3.94 +1.5% | 3 qtrs — |
| 23 | STONEPINE CAPITAL MANAGEMENT, LLC | 593.6K -462.8K (-43.8%) | 2.37M -1.2M (-34.3%) | 8.01% -6.243 pp | 1.73% -1.204 pp | USD3.42 +17.0% | 2 qtrs — |
| 24 | SILVERARC CAPITAL MANAGEMENT, LLC | 357.4K +357.4K (+100.0%) | 1.43M +1.4M (+100.0%) | 4.82% +4.821 pp | 0.20% +0.199 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 25 | STATE STREET CORP | 198.2K +159.5K (+411.8%) | 792.9K +660.5K (+498.6%) | 2.67% +2.152 pp | 0.00% +0.000 pp | USD3.77 +6.1% | 3 qtrs — |
| 26 | NORTHERN TRUST CORP | 178.2K +178.2K (+100.0%) | 712.9K +712.9K (+100.0%) | 2.40% +2.404 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 27 | PALE FIRE CAPITAL SE | 167.6K -13.3K (-7.3%) | 670.4K +51.9K (+8.4%) | 2.26% -0.179 pp | 0.05% -0.023 pp | USD2.92 +37.0% | 3 qtrs — |
| 28 | AFFINITY ASSET ADVISORS, LLC | 145.0K +145.0K (+100.0%) | 580.0K +580.0K (+100.0%) | 1.96% +1.956 pp | 0.03% +0.033 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 29 | CITADEL ADVISORS LLC | 128.7K +128.7K (+100.0%) | 514.7K +514.7K (+100.0%) | 1.74% +1.736 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 30 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 127.9K +— (+0.0%) | 511.6K +74.2K (+17.0%) | 1.73% +0.000 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 31 | PALUMBO WEALTH MANAGEMENT LLC | 113.4K +18.0K (+18.9%) | 453.4K +127.4K (+39.1%) | 1.53% +0.243 pp | 0.11% +0.008 pp | USD3.51 +14.0% | 2 qtrs — |
| 32 | OMERS ADMINISTRATION CORP | 109.2K +109.2K (+100.0%) | 436.8K +436.8K (+100.0%) | 1.47% +1.473 pp | 0.00% +0.003 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 33 | JANE STREET GROUP, LLC | 91.4K +91.4K (+100.0%) | 365.7K +365.7K (+100.0%) | 1.23% +1.233 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 3 qtrs — |
| 34 | MARSHALL WACE, LLP | 80.5K +80.5K (+100.0%) | 321.8K +321.8K (+100.0%) | 1.09% +1.085 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 35 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 79.1K +79.1K (+100.0%) | 316.3K +316.3K (+100.0%) | 1.07% +1.067 pp | 0.00% +0.003 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 36 | QUBE RESEARCH & TECHNOLOGIES LTD | 67.7K +67.7K (+100.0%) | 271.0K +271.0K (+100.0%) | 0.91% +0.914 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 37 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 66.8K +66.8K (+100.0%) | 267.2K +267.2K (+100.0%) | 0.90% +0.901 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 38 | BALYASNY ASSET MANAGEMENT L.P. | 64.5K +64.5K (+100.0%) | 258.0K +258.0K (+100.0%) | 0.87% +0.870 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 39 | BARCLAYS PLC | 57.5K +57.5K (+100.0%) | 230.0K +230.0K (+100.0%) | 0.78% +0.776 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 40 | MILLENNIUM MANAGEMENT LLC | 56.0K -8.8K (-13.6%) | 223.9K +2.3K (+1.0%) | 0.76% -0.119 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 41 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 43.3K +43.3K (+100.0%) | 173.0K +173.0K (+100.0%) | 0.58% +0.584 pp | 0.00% +0.003 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 42 | BANK OF AMERICA CORP /DE/ | 35.8K +16.5K (+85.3%) | 143.0K +77.0K (+116.7%) | 0.48% +0.222 pp | 0.00% +0.000 pp | USD2.87 +39.4% | 3 qtrs — |
| 43 | CITIGROUP INC | 32.3K +32.3K (+100,937.5%) | 129.3K +129.2K (+118,549.5%) | 0.44% +0.436 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 3 qtrs — |
| 44 | HUDSON BAY CAPITAL MANAGEMENT LP | 32.2K +32.2K (+100.0%) | 129.0K +129.0K (+100.0%) | 0.43% +0.435 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 45 | JEFFERIES FINANCIAL GROUP INC. | 26.1K +26.1K (+100.0%) | 104.5K +104.5K (+100.0%) | 0.35% +0.352 pp | 0.00% +0.001 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 46 | MAN GROUP PLC | 24.2K +24.2K (+100.0%) | 96.7K +96.7K (+100.0%) | 0.33% +0.326 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 47 | VIRTU FINANCIAL LLC | 22.5K +22.5K (+100.0%) | 90.0K +90.0K (+100.0%) | 0.30% +0.303 pp | 0.00% +0.004 pp | USD4.00 +0.0% | 3 qtrs — |
| 48 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 22.2K +22.2K (+100.0%) | 88.8K +88.8K (+100.0%) | 0.30% +0.300 pp | 0.00% +0.003 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 49 | STIFEL FINANCIAL CORP | 20.5K +20.5K (+100.0%) | 82.0K +82.0K (+100.0%) | 0.28% +0.277 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 50 | TWO SIGMA INVESTMENTS, LP | 17.2K +3.4K (+24.4%) | 69.0K +21.6K (+45.4%) | 0.23% +0.046 pp | 0.00% +0.000 pp | USD3.53 +13.3% | 2 qtrs — |
| 51 | CREATIVE PLANNING | 16.4K +16.4K (+100.0%) | 65.7K +65.7K (+100.0%) | 0.22% +0.222 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 52 | CAXTON CORP | 15.6K +15.6K (+100.0%) | 62.2K +62.2K (+100.0%) | 0.21% +0.210 pp | 1.45% +1.454 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 53 | SQUAREPOINT OPS LLC | 12.5K +12.5K (+100.0%) | 50.1K +50.1K (+100.0%) | 0.17% +0.169 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 3 qtrs — |
| 54 | TOWER RESEARCH CAPITAL LLC (TRC) | 10.4K -233.0 (-2.2%) | 41.8K +5.3K (+14.4%) | 0.14% -0.003 pp | 0.00% +0.000 pp | USD2.68 +49.3% | 3 qtrs — |
| 55 | JPMORGAN CHASE & CO | 4.6K +4.5K (+13,781.8%) | 18.3K +18.2K (+16,115.9%) | 0.06% +0.061 pp | 0.00% +0.000 pp | USD3.98 +0.5% | 3 qtrs — |
| 56 | UBS GROUP AG | 4.1K -155.7K (-97.4%) | 16.5K -530.1K (-97.0%) | 0.06% -2.100 pp | 0.00% 0.000 pp | USD2.37 +68.8% | 3 qtrs — |
| 57 | GROUP ONE TRADING, L.P. | 4.0K +— (+0.0%) | 16.0K +2.3K (+17.0%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 58 | SIGNATUREFD, LLC | 2.8K +2.8K (+100.0%) | 11.0K +11.0K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 59 | CIBC PRIVATE WEALTH GROUP, LLC | 2.2K +— (+0.0%) | 8.7K +1.3K (+17.0%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 60 | PNC FINANCIAL SERVICES GROUP, INC. | 1.8K +— (+0.0%) | 7.0K +1.0K (+17.0%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 61 | RUSSELL INVESTMENTS GROUP, LTD. | 729.00 +— (+0.0%) | 2.9K +423.0 (+17.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 62 | ALLWORTH FINANCIAL LP | 715.00 +715.0 (+100.0%) | 2.9K +2.9K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 63 | BLEICHROEDER LP | 595.00 +— (+0.0%) | 2.4K +345.0 (+17.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 64 | BNP PARIBAS ARBITRAGE, SNC | 511.00 -43.0 (-7.8%) | 2.0K +149.0 (+7.9%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 65 | FARTHER FINANCE ADVISORS, LLC | 331.00 +331.0 (+100.0%) | 1.3K +1.3K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 66 | RONALD BLUE TRUST, INC. | 284.00 +— (+0.0%) | 1.1K +165.0 (+17.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.90 +110.5% | 3 qtrs — |
| 67 | FORTITUDE FAMILY OFFICE, LLC | 137.00 +137.0 (+100.0%) | 548.00 +548.0 (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 68 | SBI SECURITIES CO., LTD. | 50.00 -166.0 (-76.9%) | 200.00 -539.0 (-72.9%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD1.88 +112.8% | 3 qtrs — |
| 69 | JONES FINANCIAL COMPANIES LLLP | 38.00 +— (+0.0%) | 152.00 +21.0 (+16.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.89 +111.6% | 3 qtrs — |
| 70 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 33.00 +— (+0.0%) | 132.00 +19.0 (+16.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.39 +18.0% | 2 qtrs — |
| 71 | NEWEDGE ADVISORS, LLC | 33.00 +— (+0.0%) | 132.00 +19.0 (+16.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.88 +112.8% | 3 qtrs — |
| 72 | HIGHMARK WEALTH MANAGEMENT LLC | 6.00 +— (+0.0%) | 24.00 +3.0 (+14.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.83 +118.6% | 3 qtrs — |
| 73 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 5.00 +5.0 (+100.0%) | 20.00 +20.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 +0.0% | 1 qtrs NEW |
| 74 | ROYAL BANK OF CANADA | — -2.5K (-100.0%) | — -9.0K (-100.0%) | 0.00% -0.034 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 75 | BOOTHBAY FUND MANAGEMENT, LLC | — -344.0K (-100.0%) | — -1.2M (-100.0%) | 0.00% -4.640 pp | 0.00% -0.017 pp | USD— | 2 qtrs SOLD |
| 76 | RENAISSANCE TECHNOLOGIES LLC | — -19.2K (-100.0%) | — -65.6K (-100.0%) | 0.00% -0.259 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 77 | TD WATERHOUSE CANADA INC. | — -1.5K (-100.0%) | — -5.4K (-100.0%) | 0.00% -0.020 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 78 | KINGDON CAPITAL MANAGEMENT, L.L.C. | — -933.3K (-100.0%) | — -3.2M (-100.0%) | 0.00% -12.591 pp | 0.00% -0.396 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 38 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.51% | 112.2K | 0.20% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.21% | 454.2K | 0.50% |
| 3 | iShares Micro-Cap ETF IWC | 0.08% | 1.20M | 0.60% |
| 4 | iShares Russell 2000 Value ETF IWN | 0.02% | 3.31M | 0.24% |
| 5 | Global X - Russell 2000 ETF RSSL | 0.01% | 166.1K | 0.08% |
| 6 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 36.0K | 0.25% |
| 7 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 332.2K | 0.25% |
| 8 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 310.5K | 0.30% |
| 9 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 5.9K | 0.39% |
| 10 | iShares Russell 2000 ETF IWM | 0.01% | 8.58M | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
6.30M
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+6,297,283
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-01 | de Craecker Francoise | Director | A-Award | A | Stock Option (right to buy) | 110,000 | 4.00 | 440.0K | 0 | D | ↗ |
| 2026-01-01 | WYZGA MICHAEL S | Director | A-Award | A | Stock Option (right to buy) | 110,000 | 4.00 | 440.0K | 0 | D | ↗ |
| 2026-01-01 | Stewart Murray | Director | A-Award | A | Stock Option (right to buy) | 110,000 | 4.00 | 440.0K | 0 | D | ↗ |
| 2026-01-01 | Bridger Gary | Director | A-Award | A | Stock Option (right to buy) | 110,000 | 4.00 | 440.0K | 0 | D | ↗ |
| 2025-10-29 | Volpone John | Officer | A-Award | A | Stock Option (right to buy) | 2,329,154 | 1.42 | 3.31M | 2,329,154 | D | ↗ |
| 2025-10-29 | KIRSKE DAVID | Officer | A-Award | A | Stock Option (right to buy) | 1,552,769 | 1.42 | 2.20M | 1,552,769 | D | ↗ |
| 2025-10-29 | Craig Adam R | Director / Officer | A-Award | A | Stock Option (right to buy) | 2,329,154 | 1.42 | 3.31M | 2,329,154 | D | ↗ |
| 2025-10-23 | Craig Adam R | Director / Officer | P-Purchase | A | Common Stock | 86,206 | 2.90 | 250.0K | 376,087 | D | ↗ |
| 2025-08-14 | Volpone John | Officer | A-Award | A | Stock Option (right to buy) | 529,201 | 3.14 | 1.66M | 529,201 | D | ↗ |
| 2025-08-14 | KIRSKE DAVID | Officer | A-Award | A | Common Stock | 193,254 | 0.00 | — | 193,254 | D | ↗ |
| 2025-08-14 | Craig Adam R | Director / Officer | A-Award | A | Stock Option (right to buy) | 529,201 | 3.14 | 1.66M | 529,201 | D | ↗ |
| 2025-08-12 | Volpone John | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-12 | KIRSKE DAVID | Officer | A-Award | A | Stock Option (right to buy) | 1,073,249 | 1.42 | 1.52M | 1,073,249 | D | ↗ |
| 2025-08-12 | Craig Adam R | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,609,873 | 1.42 | 2.29M | 1,609,873 | D | ↗ |
| 2025-06-09 | de Craecker Francoise | Director | A-Award | A | Common Stock | 1,500 | 0.00 | — | 4,722 | D | ↗ |
| 2025-06-09 | Woods Keith | Director | A-Award | A | Common Stock | 1,500 | 0.00 | — | 6,000 | D | ↗ |
| 2025-06-09 | WYZGA MICHAEL S | Director | A-Award | A | Common Stock | 1,500 | 0.00 | — | 5,555 | D | ↗ |
| 2025-06-09 | Stewart Murray | Director | A-Award | A | Common Stock | 1,500 | 0.00 | — | 7,883 | D | ↗ |
| 2025-06-09 | MCGIRR DAVID W J | Director | A-Award | A | Common Stock | 1,500 | 0.00 | — | 4,722 | D | ↗ |
| 2025-06-09 | Bridger Gary | Director | A-Award | A | Common Stock | 1,500 | 0.00 | — | 4,722 | D | ↗ |
| 2025-05-20 | Thoren Natasha Fay | Officer | A-Award | A | Common Stock | 3,333 | 0.00 | — | 9,462 | D | ↗ |
| 2025-05-16 | Baldry Mark | Officer | A-Award | A | Common Stock | 1,032 | 2.48 | 2.6K | 25,337 | D | ↗ |
| 2025-02-12 | Ragan Paula | Director / Officer | A-Award | A | Common Stock | 2,250,000 | 0.00 | — | 3,337,386 | D | ↗ |
| 2025-02-12 | Mostafa Adam S. | Officer | A-Award | A | Common Stock | 850,000 | 0.00 | — | 850,000 | D | ↗ |
| 2025-02-12 | DiBiase Mary | Officer | A-Award | A | Common Stock | 650,000 | 0.00 | — | 1,140,980 | D | ↗ |
| 2025-02-12 | Baldry Mark | Officer | A-Award | A | Common Stock | 600,000 | 0.00 | — | 729,173 | D | ↗ |
| 2025-02-12 | Arbet-Engels Christophe | Officer | A-Award | A | Common Stock | 850,000 | 0.00 | — | 864,207 | D | ↗ |
| 2025-01-24 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 76,473 | 0.45 | 34.7K | 1,087,386 | D | ↗ |
| 2025-01-24 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 74,773 | 0.45 | 33.9K | 0 | D | ↗ |
| 2025-01-24 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 22,258 | 0.45 | 10.1K | 490,980 | D | ↗ |
| 2025-01-24 | Baldry Mark | Officer | S-Sale | D | Common Stock | 29,159 | 0.45 | 13.2K | 94,123 | D | ↗ |
| 2025-01-24 | Arbet-Engels Christophe | Officer | S-Sale | D | Common Stock | 11,624 | 0.45 | 5.3K | 14,207 | D | ↗ |
| 2025-01-23 | Ragan Paula | Director / Officer | A-Award | A | Common Stock | 169,940 | 0.00 | — | 1,163,859 | D | ↗ |
| 2025-01-23 | Mostafa Adam S. | Officer | A-Award | A | Common Stock | 74,773 | 0.00 | — | 74,773 | D | ↗ |
| 2025-01-23 | DiBiase Mary | Officer | A-Award | A | Common Stock | 61,178 | 0.00 | — | 513,238 | D | ↗ |
| 2025-01-23 | Baldry Mark | Officer | A-Award | A | Common Stock | 74,773 | 0.00 | — | 123,282 | D | ↗ |
| 2025-01-23 | Arbet-Engels Christophe | Officer | A-Award | A | Common Stock | 25,831 | 0.00 | — | 25,831 | D | ↗ |
| 2024-11-15 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 31,897 | 0.39 | 12.6K | 993,919 | D | ↗ |
| 2024-11-15 | Baldry Mark | Officer | P-Purchase | A | Common Stock | 13,404 | 0.34 | 4.6K | 129,173 | D | ↗ |
| 2024-10-15 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 31,897 | 0.56 | 17.9K | 1,025,816 | D | ↗ |
| 2024-10-07 | Taveras Arthur | Officer | S-Sale | D | Common Stock | 76,920 | 0.56 | 43.3K | 388,026 | D | ↗ |
| 2024-10-07 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 239,436 | 0.55 | 131.5K | 1,057,713 | D | ↗ |
| 2024-10-07 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 230,645 | 0.55 | 126.9K | 0 | D | ↗ |
| 2024-10-07 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 67,695 | 0.57 | 38.3K | 452,060 | D | ↗ |
| 2024-10-07 | Baldry Mark | Officer | S-Sale | D | Common Stock | 11,127 | 0.58 | 6.5K | 48,509 | D | ↗ |
| 2024-10-04 | Taveras Arthur | Officer | A-Award | A | Common Stock | 230,645 | 0.00 | — | 464,946 | D | ↗ |
| 2024-10-04 | Ragan Paula | Director / Officer | A-Award | A | Common Stock | 532,081 | 0.00 | — | 1,297,149 | D | ↗ |
| 2024-10-04 | Mostafa Adam S. | Officer | A-Award | A | Common Stock | 230,645 | 0.00 | — | 230,645 | D | ↗ |
| 2024-10-04 | DiBiase Mary | Officer | A-Award | A | Common Stock | 230,645 | 0.00 | — | 519,755 | D | ↗ |
| 2024-10-04 | Baldry Mark | Officer | A-Award | A | Common Stock | 34,946 | 0.00 | — | 59,636 | D | ↗ |
| 2024-09-09 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 2,642 | 0.66 | 1.7K | 289,110 | — | ↗ |
| 2024-06-10 | de Craecker Francoise | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 96,667 | — | ↗ |
| 2024-06-10 | Woods Keith | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 135,000 | — | ↗ |
| 2024-06-10 | WYZGA MICHAEL S | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 121,667 | — | ↗ |
| 2024-06-10 | Stewart Murray | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 191,504 | — | ↗ |
| 2024-06-10 | MCGIRR DAVID W J | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 96,667 | — | ↗ |
| 2024-06-10 | Lawton Alison Frances | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 96,667 | — | ↗ |
| 2024-06-10 | Bridger Gary | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 96,667 | — | ↗ |
| 2024-06-10 | Aliski William | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 96,667 | — | ↗ |
| 2024-05-17 | Baldry Mark | Officer | P-Purchase | A | Common Stock | 21,646 | 0.68 | 14.7K | 115,769 | D | ↗ |
| 2024-03-11 | Taveras Arthur | Officer | S-Sale | D | Common Stock | 14,235 | 0.88 | 12.6K | 234,301 | — | ↗ |
| 2024-03-11 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 49,678 | 0.88 | 43.9K | 765,068 | — | ↗ |
| 2024-03-11 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 52,500 | 0.88 | 46.3K | 0 | — | ↗ |
| 2024-03-11 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 15,409 | 0.88 | 13.6K | 291,752 | — | ↗ |
| 2024-02-13 | Taveras Arthur | Officer | A-Award | A | Stock Appreciation Right | 428,248 | 0.92 | 394.4K | 428,248 | — | ↗ |
| 2024-02-13 | Ragan Paula | Director / Officer | A-Award | A | Stock Appreciation Right | 1,189,578 | 0.92 | 1.10M | 1,189,578 | — | ↗ |
| 2024-02-13 | Mostafa Adam S. | Officer | A-Award | A | Stock Appreciation Right | 523,414 | 0.92 | 482.1K | 523,414 | — | ↗ |
| 2024-02-13 | DiBiase Mary | Officer | A-Award | A | Stock Appreciation Right | 428,248 | 0.92 | 394.4K | 428,248 | — | ↗ |
| 2024-02-13 | Baldry Mark | Officer | A-Award | A | Stock Appreciation Right | 523,414 | 0.92 | 482.1K | 523,414 | — | ↗ |
| 2024-02-13 | Arbet-Engels Christophe | Officer | A-Award | A | Stock Appreciation Right | 180,816 | 0.92 | 166.5K | 180,816 | — | ↗ |
| 2024-02-12 | Taveras Arthur | Officer | S-Sale | D | Common Stock | 787 | 1.01 | 792.67 | 248,536 | — | ↗ |
| 2024-02-12 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 21,695 | 1.01 | 21.9K | 814,746 | — | ↗ |
| 2024-02-12 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 27,721 | 1.01 | 28.0K | 52,500 | — | ↗ |
| 2024-02-12 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 3,683 | 1.01 | 3.7K | 307,161 | — | ↗ |
| 2023-11-03 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 39,906 | 0.90 | 35.9K | 836,441 | — | ↗ |
| 2023-11-01 | Taveras Arthur | Officer | S-Sale | D | Common Stock | 67,695 | 0.73 | 49.4K | 249,323 | — | ↗ |
| 2023-11-01 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 199,531 | 0.73 | 145.7K | 876,347 | — | ↗ |
| 2023-11-01 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 230,645 | 0.73 | 168.4K | 80,221 | — | ↗ |
| 2023-11-01 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 67,695 | 0.73 | 49.4K | 310,844 | — | ↗ |
| 2023-11-01 | Baldry Mark | Officer | S-Sale | D | Common Stock | 10,257 | 0.73 | 7.5K | 24,690 | — | ↗ |
| 2023-10-31 | Taveras Arthur | Officer | A-Award | A | Common Stock | 230,645 | 0.00 | — | 317,018 | — | ↗ |
| 2023-10-31 | Ragan Paula | Director / Officer | A-Award | A | Common Stock | 532,081 | 0.00 | — | 1,075,878 | — | ↗ |
| 2023-10-31 | Mostafa Adam S. | Officer | A-Award | A | Common Stock | 230,645 | 0.00 | — | 310,866 | — | ↗ |
| 2023-10-31 | DiBiase Mary | Officer | A-Award | A | Common Stock | 230,645 | 0.00 | — | 378,539 | — | ↗ |
| 2023-10-31 | Baldry Mark | Officer | A-Award | A | Common Stock | 34,947 | 0.00 | — | 34,947 | — | ↗ |
| 2023-10-16 | Woods Keith | Director | A-Award | A | Common Stock | 90,000 | 0.00 | — | 90,000 | — | ↗ |
| 2023-09-08 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 2,642 | 1.25 | 3.3K | 147,894 | — | ↗ |
| 2023-08-31 | Arbet-Engels Christophe | Officer | A-Award | A | Stock Option (right to buy) | 1,250,000 | 1.28 | 1.60M | 1,250,000 | — | ↗ |
| 2023-08-18 | WYZGA MICHAEL S | Director | P-Purchase | A | Common Stock | 25,000 | 1.20 | 29.9K | 76,667 | — | ↗ |
| 2023-08-16 | Arbet-Engels Christophe | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-10 | Stewart Murray | Director / Officer | S-Sale | D | Common Stock | 130,056 | 1.06 | 137.9K | 146,504 | — | ↗ |
| 2023-08-09 | Stewart Murray | Director / Officer | A-Award | A | Common Stock | 269,893 | 0.00 | — | 276,560 | — | ↗ |
| 2023-06-30 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 2,641 | 1.89 | 5.0K | 80,221 | — | ↗ |
| 2023-06-30 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 464 | 1.89 | 876.96 | 150,536 | — | ↗ |
| 2023-06-23 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 6,724 | 1.92 | 12.9K | 543,797 | — | ↗ |
| 2023-06-23 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 5,417 | 1.93 | 10.5K | 82,862 | — | ↗ |
| 2023-06-23 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 857 | 1.93 | 1.7K | 151,000 | — | ↗ |
| 2023-06-15 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 6,724 | 2.23 | 15.0K | 550,521 | — | ↗ |
| 2023-06-15 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 5,417 | 2.22 | 12.0K | 88,279 | — | ↗ |
| 2023-06-15 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 857 | 2.23 | 1.9K | 151,857 | — | ↗ |
| 2023-06-13 | de Craecker Francoise | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 51,667 | — | ↗ |
| 2023-06-13 | WYZGA MICHAEL S | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 51,667 | — | ↗ |
| 2023-06-13 | MCGIRR DAVID W J | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 51,667 | — | ↗ |
| 2023-06-13 | Lawton Alison Frances | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 51,667 | — | ↗ |
| 2023-06-13 | Bridger Gary | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 51,667 | — | ↗ |
| 2023-06-13 | Aliski William | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 51,667 | — | ↗ |
| 2023-05-31 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 6,292 | 1.95 | 12.3K | 557,245 | — | ↗ |
| 2023-03-10 | Taveras Arthur | Officer | S-Sale | D | Common Stock | 16,806 | 0.84 | 14.1K | 86,373 | — | ↗ |
| 2023-03-10 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 49,678 | 0.84 | 41.7K | 563,537 | — | ↗ |
| 2023-03-10 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 52,500 | 0.84 | 44.1K | 93,696 | — | ↗ |
| 2023-03-10 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 18,192 | 0.84 | 15.3K | 152,714 | — | ↗ |
| 2023-02-13 | Taveras Arthur | Officer | S-Sale | D | Common Stock | 928 | 0.93 | 863.04 | 103,179 | — | ↗ |
| 2023-02-13 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 21,695 | 0.93 | 20.2K | 613,215 | — | ↗ |
| 2023-02-13 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 27,721 | 0.93 | 25.8K | 146,196 | — | ↗ |
| 2023-02-13 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 4,348 | 0.93 | 4.0K | 170,906 | — | ↗ |
| 2022-11-07 | Taveras Arthur | Officer | A-Award | A | Stock Appreciation Right | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2022-11-07 | Ragan Paula | Officer | A-Award | A | Stock Appreciation Right | 3,438,335 | 0.00 | — | 3,438,335 | — | ↗ |
| 2022-11-07 | Mostafa Adam S. | Officer | A-Award | A | Stock Appreciation Right | 1,350,000 | 0.00 | — | 1,350,000 | — | ↗ |
| 2022-11-07 | DiBiase Mary | Officer | A-Award | A | Stock Appreciation Right | 1,350,000 | 0.00 | — | 1,350,000 | — | ↗ |
| 2022-11-03 | Baldry Mark | Officer | A-Award | A | Stock Option (right to buy) | 341,000 | 1.89 | 644.5K | 341,000 | — | ↗ |
| 2022-08-17 | Ragan Paula | Officer | S-Sale | D | Common Stock | 13,448 | 0.00 | — | 634,910 | — | ↗ |
| 2022-08-17 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 10,834 | 0.00 | — | 173,917 | — | ↗ |
| 2022-08-17 | Meisner Derek M | Officer | S-Sale | D | Common Stock | 8,334 | 0.00 | — | 145,155 | — | ↗ |
| 2022-08-17 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 1,713 | 0.00 | — | 177,896 | — | ↗ |
| 2022-06-30 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 2,641 | 0.00 | — | 184,751 | — | ↗ |
| 2022-06-30 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 1,578 | 0.00 | — | 179,609 | — | ↗ |
| 2022-06-24 | Ragan Paula | Officer | S-Sale | D | Common Stock | 6,724 | 0.00 | — | 648,358 | — | ↗ |
| 2022-06-24 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 5,416 | 0.00 | — | 187,392 | — | ↗ |
| 2022-06-24 | Meisner Derek M | Officer | S-Sale | D | Common Stock | 4,166 | 0.00 | — | 153,489 | — | ↗ |
| 2022-06-24 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 856 | 0.00 | — | 181,187 | — | ↗ |
| 2022-06-16 | Ragan Paula | Officer | S-Sale | D | Common Stock | 6,724 | 0.00 | — | 655,082 | — | ↗ |
| 2022-06-16 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 5,416 | 0.00 | — | 192,808 | — | ↗ |
| 2022-06-16 | Meisner Derek M | Officer | S-Sale | D | Common Stock | 4,166 | 0.00 | — | 157,655 | — | ↗ |
| 2022-06-16 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 856 | 0.00 | — | 182,043 | — | ↗ |
| 2022-06-06 | de Craecker Francoise | Director | A-Award | A | Common Stock | 6,667 | 0.00 | — | 6,667 | — | ↗ |
| 2022-06-06 | WYZGA MICHAEL S | Director | A-Award | A | Common Stock | 6,667 | 0.00 | — | 6,667 | — | ↗ |
| 2022-06-06 | Stewart Murray | Director | A-Award | A | Common Stock | 6,667 | 0.00 | — | 6,667 | — | ↗ |
| 2022-06-06 | MCGIRR DAVID W J | Director | A-Award | A | Common Stock | 6,667 | 0.00 | — | 6,667 | — | ↗ |
| 2022-06-06 | Lawton Alison Frances | Director | A-Award | A | Common Stock | 6,667 | 0.00 | — | 6,667 | — | ↗ |
| 2022-06-06 | Bridger Gary | Director | A-Award | A | Common Stock | 6,667 | 0.00 | — | 6,667 | — | ↗ |
| 2022-06-06 | Aliski William | Director | A-Award | A | Common Stock | 6,667 | 0.00 | — | 6,667 | — | ↗ |
| 2022-06-03 | Ragan Paula | Officer | S-Sale | D | Common Stock | 6,292 | 1.21 | 7.6K | 661,806 | — | ↗ |
| 2022-03-01 | Taveras Arthur | Officer | A-Award | A | Common Stock | 97,000 | 0.00 | — | 104,107 | — | ↗ |
| 2022-03-01 | Ragan Paula | Officer | A-Award | A | Common Stock | 220,789 | 0.00 | — | 668,098 | — | ↗ |
| 2022-03-01 | Mostafa Adam S. | Officer | A-Award | A | Common Stock | 105,000 | 0.00 | — | 198,224 | — | ↗ |
| 2022-03-01 | Meisner Derek M | Officer | A-Award | A | Common Stock | 105,000 | 0.00 | — | 161,821 | — | ↗ |
| 2022-03-01 | DiBiase Mary | Officer | A-Award | A | Common Stock | 105,000 | 0.00 | — | 182,899 | — | ↗ |
| 2022-03-01 | Cadavid Diego | Officer | A-Award | A | Common Stock | 97,000 | 0.00 | — | 104,107 | — | ↗ |
| 2022-02-11 | Taveras Arthur | Officer | F-InKind | D | Common Stock | 928 | 0.00 | — | 7,107 | — | ↗ |
| 2022-02-11 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 21,695 | 1.52 | 33.0K | 447,309 | — | ↗ |
| 2022-02-11 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 27,721 | 1.52 | 42.1K | 93,224 | — | ↗ |
| 2022-02-11 | Meisner Derek M | Officer | S-Sale | D | Common Stock | 15,909 | 1.53 | 24.3K | 56,821 | — | ↗ |
| 2022-02-11 | DiBiase Mary | Officer | S-Sale | D | Common Stock | 12,545 | 1.52 | 19.1K | 77,899 | — | ↗ |
| 2022-02-11 | Cadavid Diego | Officer | S-Sale | D | Common Stock | 928 | 1.53 | 1.4K | 7,107 | — | ↗ |
| 2021-10-14 | de Craecker Francoise | Director | A-Award | A | Stock Option (right to buy) | 12,250 | 5.37 | 65.8K | 12,250 | — | ↗ |
| 2021-09-08 | DiBiase Mary | Officer | A-Award | A | Common Stock | 27,000 | 0.00 | — | 90,444 | — | ↗ |
| 2021-08-17 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 13,448 | 5.10 | 68.6K | 469,004 | — | ↗ |
| 2021-08-17 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 10,832 | 5.10 | 55.2K | 120,945 | — | ↗ |
| 2021-08-17 | Meisner Derek M | Officer | S-Sale | D | Common Stock | 8,332 | 5.10 | 42.5K | 72,730 | — | ↗ |
| 2021-07-15 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 13,448 | 5.78 | 77.7K | 482,452 | — | ↗ |
| 2021-06-30 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 2,641 | 6.64 | 17.5K | 131,777 | — | ↗ |
| 2021-06-24 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 5,417 | 7.01 | 38.0K | 134,418 | — | ↗ |
| 2021-06-24 | Meisner Derek M | Officer | S-Sale | D | Common Stock | 4,166 | 7.00 | 29.2K | 81,062 | — | ↗ |
| 2021-06-23 | Ragan Paula | Director / Officer | A-Award | A | Common Stock | 44,826 | 0.00 | — | 495,900 | — | ↗ |
| 2021-06-23 | Mostafa Adam S. | Officer | A-Award | A | Common Stock | 16,250 | 0.00 | — | 139,835 | — | ↗ |
| 2021-06-23 | Meisner Derek M | Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 85,228 | — | ↗ |
| 2021-06-15 | Ragan Paula | Director / Officer | A-Award | A | Common Stock | 44,826 | 0.00 | — | 451,074 | — | ↗ |
| 2021-06-15 | Mostafa Adam S. | Officer | A-Award | A | Common Stock | 16,250 | 0.00 | — | 129,002 | — | ↗ |
| 2021-06-15 | Meisner Derek M | Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 76,894 | — | ↗ |
| 2021-06-02 | WYZGA MICHAEL S | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 9.50 | 57.0K | 6,000 | — | ↗ |
| 2021-06-02 | Stewart Murray | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 9.50 | 57.0K | 6,000 | — | ↗ |
| 2021-06-02 | Russo Rene | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 9.50 | 57.0K | 6,000 | — | ↗ |
| 2021-06-02 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 2,400 | 9.50 | 22.8K | 406,248 | — | ↗ |
| 2021-06-02 | MCGIRR DAVID W J | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 9.50 | 57.0K | 6,000 | — | ↗ |
| 2021-06-02 | Lawton Alison Frances | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 9.50 | 57.0K | 6,000 | — | ↗ |
| 2021-06-02 | Bridger Gary | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 9.50 | 57.0K | 6,000 | — | ↗ |
| 2021-06-02 | Aliski William | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 9.50 | 57.0K | 6,000 | — | ↗ |
| 2021-06-01 | Ragan Paula | Officer | S-Sale | D | Common Stock | 4,104 | 9.41 | 38.6K | 408,648 | — | ↗ |
| 2021-05-03 | Ragan Paula | Officer | S-Sale | D | Common Stock | 2,400 | 8.33 | 20.0K | 412,752 | — | ↗ |
| 2021-04-05 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 2,400 | 9.17 | 22.0K | 415,152 | — | ↗ |
| 2021-03-24 | Taveras Arthur | Officer | A-Award | A | Common Stock | 8,035 | 0.00 | — | 8,035 | — | ↗ |
| 2021-03-24 | Ragan Paula | Director / Officer | A-Award | A | Common Stock | 144,629 | 0.00 | — | 417,552 | — | ↗ |
| 2021-03-24 | Mostafa Adam S. | Officer | A-Award | A | Common Stock | 83,163 | 0.00 | — | 112,752 | — | ↗ |
| 2021-03-24 | Meisner Derek M | Officer | A-Award | A | Common Stock | 47,728 | 0.00 | — | 64,394 | — | ↗ |
| 2021-03-24 | Cadavid Diego | Officer | A-Award | A | Common Stock | 8,035 | 0.00 | — | 8,035 | — | ↗ |
| 2021-03-02 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 2,400 | 9.74 | 23.4K | 272,923 | — | ↗ |
| 2021-02-02 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 2,400 | 7.88 | 18.9K | 275,323 | — | ↗ |
| 2021-01-05 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 2,400 | 7.00 | 16.8K | 277,723 | — | ↗ |
| 2020-12-31 | Cadavid Diego | Officer | A-Award | A | Stock Option (right to buy) | 121,500 | 6.43 | 781.2K | 121,500 | — | ↗ |
| 2020-12-23 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 4,800 | 7.00 | 33.6K | 280,123 | — | ↗ |
| 2020-12-14 | Cadavid Diego | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-30 | Taveras Arthur | Officer | A-Award | A | Stock Option (right to buy) | 121,150 | 6.60 | 799.6K | 121,150 | — | ↗ |
| 2020-11-02 | Taveras Arthur | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | Stewart Murray | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 7.27 | 72.7K | 10,000 | — | ↗ |
| 2020-10-05 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 1,797 | 7.00 | 12.6K | 284,923 | — | ↗ |
| 2020-10-05 | Lawton Alison Frances | Director | A-Award | A | Stock Option (right to buy) | 6,854 | 7.33 | 50.2K | 6,854 | — | ↗ |
| 2020-10-05 | Bridger Gary | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.33 | 219.9K | 30,000 | — | ↗ |
| 2020-10-02 | Ragan Paula | Director / Officer | S-Sale | D | Common Stock | 603 | 7.00 | 4.2K | 286,720 | — | ↗ |
| 2020-09-21 | Mostafa Adam S. | Officer | S-Sale | D | Common Stock | 10,834 | 7.08 | 76.7K | 29,589 | — | ↗ |
| 2020-09-09 | Skerlj Renato | Officer | S-Sale | D | Common Stock | 5,834 | 8.05 | 47.0K | 42,076 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-6.1K
Shares Outstanding
11.41M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Adam R. Craig, M.D., Ph.D., M.B.A. Executive Chairman | 179.6K | — | — | 6.41M | 114.5K | 139.00 | 6.71M | 95.61% | ↗ |
| 2 | 2025 | John Volpone, M.B.A., President and Chief Operating Officer | 176.5K | — | — | 6.41M | 75.0K | 5.0K | 6.67M | 96.15% | ↗ |
| 3 | 2025 | David Kirske, Chief Financial Officer, Treasurer and Corporate Secretary | 194.2K | 120.0K | — | 4.18M | 103.1K | 901.00 | 4.60M | 90.91% | ↗ |
| 4 | 2025 | Paula Ragan, Ph.D. Former President and Chief Executive Officer | 420.2K | — | 1.08M | — | — | 1.14M | 2.64M | 40.96% | ↗ |
| 5 | 2024 | Paula Ragan, Ph.D. President and Chief Executive Officer | 654.2K | — | 313.0K | 857.7K | 305.8K | 14.4K | 2.15M | 54.57% | ↗ |
| 6 | 2024 | Paula Ragan, Ph.D. Former President and Chief Executive Officer | 654.2K | — | 313.0K | 857.7K | 305.8K | 14.4K | 2.15M | 54.57% | ↗ |
| 7 | 2024 | Adam S. Mostafa Chief Financial Officer, Treasurer and Secretary | 510.0K | 102.0K | 137.7K | 377.4K | 179.5K | 619.00 | 1.31M | 39.40% | ↗ |
| 8 | 2024 | Mark Baldry, Chief Commercial Officer | 475.0K | — | 137.7K | 377.4K | 167.2K | 14.4K | 1.17M | 43.96% | ↗ |
| 9 | 2023 | Paula Ragan, Ph.D. President and Chief Executive Officer | 620.1K | — | 1.04M | — | 375.1K | 13.8K | 2.04M | 50.66% | ↗ |
| 10 | 2023 | Christophe Arbet-Engels, Ph.D M.D. Chief Medical Officer | 179.6K | 200.0K | — | 1.26M | — | 205.00 | 1.64M | 76.80% | ↗ |
| 11 | 2023 | Adam S. Mostafa Chief Financial Officer, Treasurer and Secretary | 486.2K | — | 452.1K | — | 214.0K | 592.00 | 1.15M | 39.21% | ↗ |
| 12 | 2022 | Paula Ragan, Ph.D. President and Chief Executive Officer | 583.5K | 58.8K | 476.9K | 2.43M | 308.6K | 12.8K | 3.87M | 75.12% | ↗ |
| 13 | 2022 | Adam S. Mostafa Chief Financial Officer, Treasurer and Secretary | 459.0K | 46.1K | 226.8K | 954.9K | 193.6K | 569.00 | 1.88M | 62.83% | ↗ |
| 14 | 2022 | Mary DiBiase Chief Operating Officer | 426.3K | 42.8K | 226.8K | 954.9K | 179.7K | 12.8K | 1.84M | 64.11% | ↗ |
| 15 | 2021 | Paula Ragan, Ph.D. President and Chief Executive Officer | 562.1K | — | 1.26M | — | 309.3K | 11.6K | 2.14M | 58.76% | ↗ |
| 16 | 2021 | Adam S. Mostafa Chief Financial Officer, Treasurer and Secretary | 430.2K | — | 723.5K | — | 185.2K | — | 1.34M | 54.04% | ↗ |
| 17 | 2021 | Derek Meisner Chief Legal Officer and Corporate Secretary | 428.2K | — | 415.2K | — | 184.3K | 11.5K | 1.04M | 39.95% | ↗ |
| 18 | 2020 | Paula Ragan, Ph.D. President, Chief Executive Officer, Corporate Secretary and Director | 543.4K | — | 1.69M | — | 271.7K | 8.2K | 2.51M | 67.25% | ↗ |
| 19 | 2020 | Paula Ragan, Ph.D. President and Chief Executive Officer | 543.4K | — | 1.69M | — | 271.7K | 7.6K | 2.51M | 67.27% | ↗ |
| 20 | 2020 | Adam S. Mostafa Chief Financial Officer and Treasurer | 400.0K | — | 613.0K | — | 163.6K | — | 1.18M | 52.10% | ↗ |
| 21 | 2020 | Derek Meisner General Counsel | 400.0K | 67.5K | 471.5K | — | 162.4K | 12.0K | 1.11M | 42.35% | ↗ |
| 22 | 2020 | Derek Meisner Chief Legal Officer and Corporate Secretary | 400.0K | 67.5K | 471.5K | — | 162.4K | 11.4K | 1.11M | 42.37% | ↗ |
| 23 | 2019 | Paula Ragan, Ph.D. President, Chief Executive Officer, Corporate Secretary and Director | 492.3K | — | 824.9K | 893.5K | 286.0K | 1.2K | 2.50M | 68.80% | ↗ |
| 24 | 2019 | Michael Gray, M.B.A., C.P.A. Former President, Chief Executive Officer and Chief Financial Officer | 91.3K | — | — | — | — | 1.05M | 1.14M | 0.00% | ↗ |
| 25 | 2019 | E. Lynne Kelley, M.D., FACS Former Chief Medical Officer | 281.0K | — | — | 566.4K | 121.0K | 1.6K | 970.0K | 58.39% | ↗ |
| 26 | 2019 | Adam S. Mostafa Chief Financial Officer and Treasurer | 372.3K | — | 155.8K | 168.8K | 168.3K | 1.0K | 866.2K | 37.47% | ↗ |
| 27 | 2018 | René Russo, Pharm.D., BCPS Former President and Chief Executive Officer | 405.9K | — | — | 1.91M | — | 1.05M | 3.36M | 56.77% | ↗ |
| 28 | 2018 | Michael Gray, M.B.A., C.P.A. Former President, Chief Executive Officer and Chief Financial Officer | 405.2K | 181.1K | 1.03M | 1.31M | — | — | 2.93M | 79.97% | ↗ |
| 29 | 2018 | Michael Gray, M.B.A., C.P.A. Former President, Chief Executive Officer and Chief Financial Officer | 405.2K | 181.1K | 1.03M | 1.31M | — | — | 2.93M | 79.97% | ↗ |
| 30 | 2018 | Christopher Stevens, M.D. Former Chief Medical Officer | 380.0K | — | — | 595.9K | — | 329.3K | 1.31M | 45.65% | ↗ |
| 31 | 2018 | David Mantus, Ph.D. Former Chief Development Officer | 358.8K | — | — | 595.9K | — | 120.3K | 1.07M | 55.44% | ↗ |
| 32 | 2018 | Paula Ragan, Ph.D. President, Chief Executive Officer, Corporate Secretary and Director | 380.0K | — | — | 407.6K | 133.0K | 450.00 | 921.0K | 44.25% | ↗ |
| 33 | 2018 | Paula Ragan, Ph.D. President, Chief Executive Officer and Secretary | 380.0K | — | — | 407.6K | 133.0K | 450.00 | 921.0K | 44.25% | ↗ |
| 34 | 2018 | Adam S. Mostafa Chief Financial Officer and Treasurer | 109.3K | — | — | 480.8K | 38.3K | 90.00 | 628.4K | 76.51% | ↗ |
| 35 | 2017 | René Russo, Pharm.D., BCPS President and Chief Executive Officer | 388.8K | 254.1K | — | 524.2K | — | — | 1.17M | 44.92% | ↗ |
| 36 | 2017 | René Russo, Pharm.D., BCPS Former President and Chief Executive Officer | 388.8K | 254.1K | — | 524.2K | — | — | 1.17M | 44.92% | ↗ |
| 37 | 2017 | Michael Gray, M.B.A., C.P.A. Former President, Chief Executive Officer and Chief Financial Officer | 363.1K | 231.5K | — | 262.1K | — | — | 856.7K | 30.59% | ↗ |
| 38 | 2017 | Michael Gray, M.B.A., C.P.A. Chief Operating Officer and Chief Financial Officer | 363.1K | 231.5K | — | 262.1K | — | — | 856.7K | 30.59% | ↗ |
| 39 | 2017 | Paula Ragan, Ph.D. President, Chief Executive Officer and Secretary | 364.0K | — | — | 303.4K | 89.2K | 576.00 | 757.2K | 40.07% | ↗ |
| 40 | 2017 | Chris Stevens, M.D. Chief Medical Officer | 380.0K | 159.6K | — | 117.9K | — | — | 657.5K | 17.94% | ↗ |
| 41 | 2017 | Christopher Stevens, M.D. Former Chief Medical Officer | 380.0K | 159.6K | — | 117.9K | — | — | 657.5K | 17.94% | ↗ |
| 42 | 2017 | David Mantus, Ph.D. Former Chief Development Officer | 313.8K | — | — | 117.9K | — | — | 431.7K | 27.32% | ↗ |
| 43 | 2016 | René Russo, Pharm.D., BCPS President and Chief Executive Officer | 380.0K | 116.5K | — | 292.3K | — | — | 788.8K | 37.06% | ↗ |
| 44 | 2016 | Michael Gray, M.B.A., C.P.A. Chief Operating Officer and Chief Financial Officer | 292.5K | 181.9K | — | 312.9K | — | — | 787.2K | 39.75% | ↗ |
| 45 | 2016 | Chris Stevens, M.D. Chief Medical Officer | 221.8K | 153.2K | — | 162.8K | — | 176.9K | 714.7K | 22.78% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David H. Kirske | Chief Financial Officer, Treasurer & Corporate Secretary | 722.3K | male |
| Adam R. Craig | Executive Chair | 575.5K | — |
| John Volpone | President & Chief Operating Officer | 533.0K | male |
| Brian Bowersox | Vice President of Finance & Corporate Controller | — | male |
| Keith T. Flaherty | Founder & Member of Corporate Advisory Board | — | — |
| Renato T. Skerlj | Founder | — | — |
| Richard Peters | Founder | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XFOR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
